Kidney Function

Conclusions: Raloxifene treatment was useful for the prevention of BMD deterioration in postmenopausal dialysis patients with controlled iPTH levels.
PMID: 19954718 [PubMed - in process] (Source: Clinical Nephrology)

Authors: Bologa R, Levine D, Parker T, Gordon B, Lanto A, Cheigh J, Stenzel K, Rubin A,
Patients undergoing dialysis treatment have a high incidence of dyslipidemia. Rosuvastatin is a potent statin drug that improves overall lipid profiles in dyslipidemic patients. However, the pharmacokinetics of rosuvastatin has not been studied in patients with end-stage kidney disease undergoing chronic peritoneal dialysis (PD). The goals of this study are to determine the pharmacokinetics and tolerability of a single oral dose of rosuvastatin in patients undergoing continuous ambulatory PD (CAPD). This was a nonrandomized, open-label, 1-week trial. Ten stable PD patients were given a single oral dose of rosuvastatin (10 mg). Serial blood samples were obtained over the next 48 hours, and the patie…

This study suggests that antibiotic lock therapy in the treatment of refractory peritonitis can be an effective method without catheter removal.
PMID: 19954727 [PubMed - in process] (Source: Clinical Nephrology)